Agilent Technologies is a global leader in providing scientific instruments, software, and services for laboratories in the life sciences, diagnostics, and applied chemical markets. The company specializes in developing innovative solutions that enable scientists and researchers to enhance their workflows, improve productivity, and achieve more accurate results across various applications, including pharmaceuticals, environmental testing, and food safety. Agilent’s commitment to advancing science is reflected in its extensive portfolio of cutting-edge technologies and collaborative approach to supporting customers in their quest for discovery and innovation. Read More
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent strategic developments. This significant uptick reflects investor confidence in the life sciences giant's aggressive expansion into high-growth sectors,
The global healthcare sector is currently navigating a period of profound transformation, driven by aggressive regulatory changes emanating from the United States. As of late September 2025, a series of White House initiatives and legislative actions, most notably the ongoing implementation of the Inflation Reduction Act (IRA) and the pursuit
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Washington D.C. – September 30, 2025 – Shares of Agilent Technologies (NYSE: A) experienced a significant upward movement today, closing strong amidst breaking news of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE). This surge, echoing similar positive movements for other life sciences companies like
As of September 30, 2025, the financial markets are grappling with the implications of a landmark drug-pricing agreement between the White House and pharmaceutical giant Pfizer (NYSE: PFE), a move signaling a broader governmental push to significantly lower prescription drug costs. While such developments typically send ripples across the entire
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Agilent Technologies Inc. (NYSE: A) today announced the launch of its new Insight Series Alarm Resolution Systems, designed to enhance safety and streamline operations at airport security checkpoints worldwide. The Insight Series includes the Insight300M and InsightBLS, advanced liquid explosive detection systems (LEDs) that meet global regulations for screening liquids, aerosols, and gels (LAGs).
Agilent Technologies Inc. (NYSE: A) today announced the release of a new range of high performance liquid chromatography (HPLC) columns ideally suited for biotherapeutics applications. The Agilent Altura Ultra Inert HPLC Columns set a new standard in liquid chromatography performance, providing the reliability and efficiency biopharmaceutical companies need for the most demanding applications, including peptide GLP-1 and oligonucleotide therapeutic development and quality control.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 24.8 cents per share of common stock. The quarterly dividend will be paid on Oct. 22, 2025, to all shareholders of record as of the close of business on Sept. 30, 2025.
Agilent Technologies Inc. (NYSE: A) today announced that President and CEO Padraig McDonnell will participate in a fireside chat at this year’s Bank of America Global Healthcare Conference in London.
Agilent Technologies Inc. (NYSE: A) today announced that its Refurbishment Centers in Delaware, USA, and Singapore have achieved the highest level of My Green Lab Certification—Green level— an internationally recognized benchmark for laboratory sustainability.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at research tools & consumables stocks, starting with Agilent (NYSE:A).
Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place in Vienna, Austria, from September 6–10, 2025. Agilent will spotlight the European launch of its newly expanded Dako Omnis Family of instruments.
Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer. MMR IHC Panel pharmDx (Dako Omnis) is indicated as an aid to identify mismatch repair (MMR) deficient CRC patients eligible for treatment with OPDIVO® (nivolumab) in combination with YERVOY® (ipilimumab). MMR IHC Panel pharmDx (Dako Omnis) is approved for exclusive use with the Agilent Dako Omnis automated staining solution.
Shares of life sciences tools company Agilent Technologies (NYSE:A)
jumped 3.7% in the morning session after the company reported better-than-expected revenue in its second-quarter 2025 results and provided strong guidance for the upcoming quarter. For the quarter, the company announced revenue of $1.74 billion, up 10.1% year on year, surpassing analysts' expectations of $1.67 billion. Its adjusted earnings per share of $1.37 met consensus estimates. Looking ahead, Agilent's revenue guidance for the third quarter was a key positive, with its forecast of $1.83 billion at the midpoint coming in comfortably above Wall Street's projections of $1.77 billion. The strong top-line performance and optimistic near-term outlook appeared to drive investor confidence.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
Life sciences tools company Agilent Technologies (NYSE:A) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 10.1% year on year to $1.74 billion. On top of that, next quarter’s revenue guidance ($1.83 billion at the midpoint) was surprisingly good and 3.4% above what analysts were expecting. Its non-GAAP profit of $1.37 per share was in line with analysts’ consensus estimates.
